(Q51824053)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19214194%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

review article

1 reference

title

Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19214194%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19214194%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Peter Beverley

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19214194%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

1

Andrew J Pollard

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19214194%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

publication date

1 March 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19214194%20AND%20SRC:MED&resulttype=core&format=json

Nature Reviews Immunology

21 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19214194%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

volume

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19214194%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

page(s)

213-220

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19214194%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19214194%20AND%20SRC:MED&resulttype=core&format=json

Modeling future changes to the meningococcal serogroup C conjugate (MCC) vaccine program in England and Wales

21 January 2020

cites work

1 reference

The magnitude of the antibody and memory B cell responses during priming with a protein-polysaccharide conjugate vaccine in human infants is associated with the persistence of antibody and the intensity of booster response.

21 January 2018

1 reference

Social behavior and meningococcal carriage in British teenagers

21 January 2018

1 reference

The preventable burden of pneumococcal disease in the developing world

21 January 2018

1 reference

The Meningitis Vaccine Project

31 March 2020

1 reference

PREVENTION OF PNEUMOCOCCAL PNEUMONIA BY IMMUNIZATION WITH SPECIFIC CAPSULAR POLYSACCHARIDES

31 March 2020

1 reference

Mitogenic properties of the thymus-independent antigen pneumococcal polysaccharide S3.

31 March 2020

1 reference

CRM197-conjugated serogroup C meningococcal capsular polysaccharide, but not the native polysaccharide, induces persistent antigen-specific memory B cells.

31 March 2020

1 reference

Immunologic memory 5 years after meningococcal A/C conjugate vaccination in infancy.

31 March 2020

1 reference

Reconsideration of the use of meningococcal polysaccharide vaccine

31 March 2020

1 reference

Reduced antibody response to revaccination with meningococcal serogroup A polysaccharide vaccine in adults

31 March 2020

1 reference

Zwitterionic polysaccharides stimulate T cells by MHC class II-dependent interactions

31 March 2020

1 reference

Recirculating and germinal center B cells differentiate into cells responsive to polysaccharide antigens

31 March 2020

1 reference

Vaccination against encapsulated bacteria in humans: paradoxes.

31 March 2020

1 reference

Human blood IgM "memory" B cells are circulating splenic marginal zone B cells harboring a prediversified immunoglobulin repertoire

31 March 2020

1 reference

Serum antibody responses of weanling mice and two-year-old children to pneumococcal-type 6A-protein conjugate vaccines of differing saccharide chain lengths.

31 March 2020

1 reference

Comparative trial in infants of four conjugate Haemophilus influenzae type b vaccines

31 March 2020

1 reference

Acquisition of Streptococcus pneumoniae and Nonspecific Morbidity in Infants and Their Families

31 March 2020

1 reference

School‐Aged Children: A Reservoir for Continued Circulation ofHaemophilus influenzaeType b in the United Kingdom

31 March 2020

1 reference

Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination.

31 March 2020

1 reference

Serotype-specific and age-dependent generation of pneumococcal polysaccharide-specific memory B-cell and antibody responses to immunization with a pneumococcal conjugate vaccine.

31 March 2020

1 reference

Predictors of pneumococcal conjugate vaccine immunogenicity among infants and toddlers in an American Indian PnCRM7 efficacy trial

31 March 2020

1 reference

Immunogenicity of combined diphtheria, tetanus, and pertussis vaccine given at 2, 3, and 4 months versus 3, 5, and 9 months of age

31 March 2020

1 reference

Vaccination of infants with a four-dose and a three-dose vaccination schedule

31 March 2020

1 reference

Safety and immunogenicity of a combined diphtheria-tetanus-acellular pertussis-hepatitis B vaccine administered according to two different primary vaccination schedules. Multicenter Working Group

31 March 2020

1 reference

Safety and immunogenicity of a combined diphtheria-tetanus-acellular pertussis-inactivated polio vaccine-Haemophilus influenzae type b vaccine administered at 2-4-6-13 or 3-5-12 months of age

31 March 2020

1 reference

Immunogenicity of, and immunologic memory to, a reduced primary schedule of meningococcal C-tetanus toxoid conjugate vaccine in infants in the United kingdom

31 March 2020

1 reference

Immunogenicity of one, two or three doses of a meningococcal C conjugate vaccine conjugated to tetanus toxoid, given as a three-dose primary vaccination course in UK infants at 2, 3 and 4 months of age with acellular pertussis-containing DTP/Hib vac

31 March 2020

1 reference

The use of combination vaccines has improved timeliness of vaccination in children

31 March 2020

1 reference

Host and environmental factors associated with Hib in England, 1998-2002.

31 March 2020

1 reference

EstimatingHaemophilus influenzaeType b Vaccine Effectiveness in England and Wales by Use of the Screening Method

31 March 2020

1 reference

Immunogenicity and safety of a combination pneumococcal-meningococcal vaccine in infants: a randomized controlled trial

31 March 2020

1 reference

Haemophilus influenzae type b conjugate vaccines: a review of efficacy data

31 March 2020

1 reference

Quantitative measurement of "natural" and immunization-induced Haemophilus influenzae type b capsular polysaccharide antibodies

31 March 2020

1 reference

The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b

31 March 2020

1 reference

Herd immunity and pneumococcal conjugate vaccine: a quantitative model

31 March 2020

1 reference

Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine

31 March 2020

1 reference

Cost-effectiveness of pneumococcal conjugate vaccine: evidence from the first 5 years of use in the United States incorporating herd effects

31 March 2020

1 reference

Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction

31 March 2020

1 reference

Impact of Meningococcal Serogroup C Conjugate Vaccines on Carriage and Herd Immunity

31 March 2020

1 reference

Protection from routine vaccination at the age of 14 months with meningococcal serogroup C conjugate vaccine in the Netherlands

31 March 2020

1 reference

Meningococcal polysaccharide-protein conjugate vaccines.

31 March 2020

1 reference

Seroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: observational study

31 March 2020

1 reference

Effectiveness Analyses May Underestimate Protection of Infants after Group C Meningococcal Immunization

31 March 2020

1 reference

Immunological memory: the role of B cells in long-term protection against invasive bacterial pathogens.

31 March 2020

1 reference

Serogroup C meningococcal glycoconjugate vaccine in adolescents: persistence of bactericidal antibodies and kinetics of the immune response to a booster vaccine more than 3 years after immunization

31 March 2020

1 reference

Immunologic memory in Haemophilus influenzae type b conjugate vaccine failure.

31 March 2020

1 reference

Seroprotection against serogroup C meningococcal disease

31 March 2020

1 reference

APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells

31 March 2020

1 reference

Antigen dependent and independent mechanisms that sustain serum antibody levels

31 March 2020

1 reference

The Alaska Haemophilus influenzae type b experience: lessons in controlling a vaccine-preventable disease

31 March 2020

1 reference

Bacterial antigens cross-reactive with the capsular polysaccharide of Haemophilus influenzae type b.

31 March 2020

1 reference

Immunogenicity of a fourth dose of Haemophilus influenzae type b (Hib) conjugate vaccine and antibody persistence in young children from the United Kingdom who were primed with acellular or whole-cell pertussis component-containing Hib combinations i

31 March 2020

1 reference

Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story

31 March 2020

1 reference

Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial.

31 March 2020

1 reference

Antibody persistence and immunological memory at age 4 years after meningococcal group C conjugate vaccination in children in the United kingdom.

31 March 2020

1 reference

Crowding as a risk factor of meningococcal disease in Danish preschool children: a nationwide population-based case-control study.

31 March 2020

1 reference

Meningococcal disease: public health burden and control

31 March 2020

1 reference

12 December 2020

Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England

1 reference

12 December 2020

Type I Streptococcus pneumoniae carbohydrate utilizes a nitric oxide and MHC II-dependent pathway for antigen presentation

1 reference

12 December 2020

Responses of children immunized with the capsular polysaccharide of Hemophilus influenzae, type b

1 reference

12 December 2020

Immunologic memory with no detectable bactericidal antibody response to a first dose of meningococcal serogroup C conjugate vaccine at four years.

1 reference

12 December 2020

WHO position paper on Haemophilus influenzae type b conjugate vaccines. (Replaces WHO position paper on Hib vaccines previously published in the Weekly Epidemiological Record.

1 reference

12 December 2020

Comparative immunogenicity of four Haemophilus influenzae type b conjugate vaccines in Alaska Native infants

1 reference

12 December 2020

Immunologic hyporesponsiveness to serogroup C but not serogroup A following repeated meningococcal A/C polysaccharide vaccination in Saudi Arabia

1 reference

12 December 2020